The global anti-nuclear antibody test market is witnessing significant growth in the U.S., with an estimated 50 million people affected by autoimmune diseases. The rising incidence of autoimmune disorders fuels the demand for antibody tests for accurate diagnosis. Reagent rental agreements, increasing healthcare expenditure, and a growing population further drive market expansion. Recent research highlights the efficacy of the immunofluorescence technique in ANA assays, contributing to the market's growth by providing more precise disease diagnoses.
Access Full Report: https://www.databridgemarketresearch.com/reports/global-antinuclear-antibody-test-market
Data Bridge Market Research analyses that the Global Anti-Nuclear Antibody Test Market is expected CAGR of anti-nuclear antibody test market tends to be around 13% in the mentioned forecast period. The market was valued at USD 1,700.75 million in 2022 and would grow to USD 4,521.35 million by 2030. The strong market competition among diagnostic companies and manufacturers drives innovation and encourages the development of reliable and cost-effective ANA testing solutions. This competition contributes to market growth by expanding accessibility and advancing the effectiveness of ANA tests.
Key Findings of the Study
The growing aging population is expected to drive the market's growth rate
The growing aging population is a major driver of the ANA Test Market. As the elderly are more susceptible to autoimmune diseases, there is an increased demand for ANA tests to accurately diagnose and manage such conditions in older individuals. With a rising number of elderly patients seeking medical attention, healthcare providers rely on ANA tests for early detection and effective disease management, thereby propelling market growth and the need for advanced diagnostic solutions tailored to this demographic.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents And Assay Kits, Systems, Software, And Services), Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren's Syndrome, Scleroderma, And Other Diseases), Technique (Enzyme-Linked Immunoassay, Immunofluorescence Assay, And Multiplex Assay), End Users (Hospitals, Clinical Laboratories, Physician Office Laboratories, And Others End Users)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Erba Mannheim (Germany), Abbott (U.S.), Trinity Biotech (Ireland), Bio-Rad Laboratories, Inc. (U.S.). Thermo Fisher Scientific (U.S.), ZEUS Scientific, Inc. (U.S.), Grifols, S.A (Spain). BioVision Inc (U.S.)., PerkinElmer, Inc. (U.S.)., F. Hoffmann-La Roche Ltd (Switzerland), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Zimmer Biomet, (U.S.)., Smith + Nephew (U.K.), Boston Scientific Corporation (U.S.), Organogenesis Inc. (U.S.) and Arthrex, Inc (Germany)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The anti-nuclear antibody test market is segmented on the basis of product, disease, technique, and end users.
- On the basis of product, the anti-nuclear antibody test market is segmented into reagents and assay kits, systems, software, and services.
- On the basis of disease, the anti-nuclear antibody test market is segmented into rheumatoid arthritis, systemic lupus erythematosus, sjögren's syndrome, scleroderma, and other diseases.
- On the basis of technique, the anti-nuclear antibody test market is segmented into enzyme-linked immunoassay, immunofluorescence assay, and multiplex assay.
- On the basis of end users, the anti-nuclear antibody test market is segmented into hospitals, clinical laboratories, physician office laboratories, and other end users.
Major Players
Data Bridge Market Research recognizes the following companies as the major global anti-nuclear antibody test market players in global anti-nuclear antibody test market are Erba Mannheim (Germany), Abbott (U.S.), Trinity Biotech (Ireland), Bio-Rad Laboratories, Inc. (U.S.). Thermo Fisher Scientific (U.S.), ZEUS Scientific, Inc. (U.S.), Grifols, S.A (Spain). BioVision Inc (U.S.), PerkinElmer, Inc. (U.S.).
Market Developments
- In 2022, THERADIAG, a leading biotech company, announced a strategic partnership with Quotient Limited. The collaboration aims to enhance autoimmune diagnostics by utilizing Quotient's innovative MosaiQ platform. By combining their expertise, the companies seek to offer advanced and efficient diagnostic solutions for autoimmune diseases.
- In 2022, ZEUS Scientific received FDA clearance for its ZEUS dIFine IFA system, designed for use with the ANA HEp-2 indirect fluorescent antibody (IFA) assay. The clearance includes positive and negative determination and identification of eight common ANA HEp-2 staining patterns. This milestone expands ZEUS' offerings, providing more accurate and reliable ANA testing capabilities to aid in autoimmune disease diagnosis.
- In June 2022, THERADIAG and Quotient Limited reached an agreement to collaborate on advancing autoimmune diagnostics. Leveraging Quotient's MosaiQ platform, the partnership aims to enhance diagnostic capabilities for autoimmune diseases, providing more efficient and accurate solutions.
- In March 2022, ZEUS Scientific received FDA clearance for its ZEUS dIFine IFA system, specifically for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay. The FDA clearance encompasses positive and negative determination, as well as the identification of 8 common ANA HEp-2 staining patterns. This clearance expands ZEUS' diagnostic offerings, improving autoimmune disease diagnosis accuracy.
Regional Analysis
Geographically, the countries covered in the global anti-nuclear antibody test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
Asia-Pacific has been witnessing positive growth in the global anti-nuclear antibody test market during the forecast period 2023 - 2030
Throughout the forecast period, the Asia-Pacific region has experienced positive growth in the global anti-nuclear antibody test market, primarily driven by unmet clinical needs and the demand for improved diagnosis. Several countries, including India, face unmet requirements for autoimmune disease diagnostics, stimulating regional demand for ANA tests.
North America dominates in the global anti-nuclear antibody test market in the forecast period 2023 - 2030
North America dominates the market due to its well-established adoption of ANA testing, robust healthcare infrastructure, and high patient awareness. The region's increasing use of advanced diagnostic tests further enhances market growth. The presence of advanced healthcare facilities and a proactive approach towards early diagnosis of autoimmune diseases contribute to North America's dominance. Overall, the ANA Test Market in both regions is propelled by the imperative for better diagnostic solutions and comprehensive healthcare services.
For more detailed information about the global anti-nuclear antibody test market report, click here – https://www.databridgemarketresearch.com/reports/global-antinuclear-antibody-test-market
